WJ-Pure(WJ-Pure) - 在研适应症：慢性阻塞性肺疾病，阿尔茨海默症，杜氏肌营养不良症_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

VL-P22

靶点-

作用方式-

作用机制-

治疗领域

呼吸系统疾病免疫系统疾病神经系统疾病+ [3]

在研适应症

慢性阻塞性肺疾病阿尔茨海默症杜氏肌营养不良症+ [1]

非在研适应症

新型冠状病毒感染COVID-19 呼吸道感染肺纤维化+ [1]

原研机构

Vitti Labs LLC.

在研机构

Vitti Labs LLC.

非在研机构-

权益机构-

最高研发阶段临床申请

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 WJ-Pure 相关的临床试验

NCT05387278

/ Suspended临床1期

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients.
The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. .

开始日期2025-03-20

申办/合作机构

Vitti Labs LLC.

NCT05387239

/ Suspended临床2期

Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance of developing a persistent respiratory system pathology and a 10% chance of developing a severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration, reduction of exercise tolerance, and concomitant development of persistent fibrotic lung damage. This study intends to evaluate benefits of a combination of VL-P22 and VL-PX10 in Covid-19 patients exhibiting pulmonary fibrosis.

开始日期2022-11-30

申办/合作机构

Vitti Labs LLC.

100 项与 WJ-Pure 相关的临床结果

登录后查看更多信息

100 项与 WJ-Pure 相关的转化医学

登录后查看更多信息

100 项与 WJ-Pure 相关的专利（医药）

登录后查看更多信息

100 项与 WJ-Pure 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	美国	Vitti Labs LLC.	2022-11-30
COVID-19 呼吸道感染	临床2期	美国	Vitti Labs LLC.	2022-11-30
肺纤维化	临床2期	美国	Vitti Labs LLC.	2022-11-30
急性呼吸窘迫综合征	临床1期	美国	Vitti Labs LLC.	2025-03-20
慢性阻塞性肺疾病	临床申请	美国	Vitti Labs LLC.	2022-01-30
阿尔茨海默症	临床前	美国	Vitti Labs LLC.	2022-01-30
杜氏肌营养不良症	临床前	美国	Vitti Labs LLC.	2022-01-30
骨关节炎	临床前	美国	Vitti Labs LLC.	2022-01-30